Immunosuppression and Outcomes in Adult Patients with De Novo Acute Myeloid Leukemia with Normal Karyotypes

Using exome sequencing, RNA-sequencing, and functional immunologic studies, scientists characterized 28 normal karyotype (NK)-AML patients with over 5 year first remissions after chemotherapy and compared them to a well-matched group of 31 NK-AML patients who relapsed within two years.